Axsome Therapeutics (AXSM) Other financing activities (2016 - 2025)

Axsome Therapeutics (AXSM) has 10 years of Other financing activities data on file, last reported at $17.0 million in Q1 2025.

• For the quarter ending Q1 2025, Other financing activities rose 581.13% year-over-year to $17.0 million; the trailing twelve-month figure through Mar 2025 stood at $25.0 million (up 72.01% YoY), and the FY2023 full-year result was $12.4 million, up 98.67% from the prior year.
• Other financing activities advanced to $17.0 million in Q1 2025, from $2.5 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $17.0 million in Q1 2025 to a low of $176000.0 in Q2 2022.
• A 5-year average of $3.0 million and a median of $1.5 million in 2021 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities tumbled 90.49% in 2022 and soared 3632.95% in 2023, its largest moves.
• Tracing AXSM's Other financing activities over 5 years: stood at $1.1 million in 2021, then surged by 159.27% to $2.8 million in 2022, then slumped by 59.53% to $1.1 million in 2023, then soared by 118.43% to $2.5 million in 2024, then soared by 581.13% to $17.0 million in 2025.
• Business Quant data shows AXSM's Other financing activities at $17.0 million in Q1 2025, $2.5 million in Q1 2024, and $1.1 million in Q4 2023.